These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 22269146)

  • 1. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
    Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
    Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
    Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
    Takusagawa S; Yajima K; Miyashita A; Uehara S; Iwatsubo T; Usui T
    Xenobiotica; 2012 Oct; 42(10):957-67. PubMed ID: 22509825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
    Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
    Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population.
    Meijer J; van den Berg T; Huls R; Hofstede V; Niesing W; van den Beld C; Krauwinkel W
    J Pharm Biomed Anal; 2019 Apr; 167():155-160. PubMed ID: 30776753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.
    Teijlingen Rv; Meijer J; Takusagawa S; Gelderen Mv; Beld Cv; Usui T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 887-888():102-11. PubMed ID: 22317789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration.
    Chen L; Zhang Y
    Rev Assoc Med Bras (1992); 2019 Feb; 65(2):141-148. PubMed ID: 30892436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
    Prakash C; Kamel A; Anderson W; Howard H
    Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
    Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
    Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
    Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
    Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
    Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
    Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
    Prakash C; Soliman V
    Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
    Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
    Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.